



公告日期	2026/7/15
異動類別	新進藥品
異動原因	藥委會決議
異動描述	Adalimumab_搭贈 inj 40mg/0.4mL/syrg (Humira [®])復邁注射劑 (2支/盒)自即日起可開方使用。

異動內容	
料號	035551
學名	Adalimumab_搭贈
商品名	Humira
中文名	復邁注射劑 (2支/盒)
主成份及含量	40mg/0.4mL/syrg
製造廠名稱	Vetter Pharma-Fertigung GmbH & Co KG (Vetter)
產地	德國
健保代碼	
外觀/圖檔	
用法	皮下注射

小孩劑量	Juvenile idiopathic arthritis (JIA), Noninfectious uveitis: Children ≥2 years and Adolescents: 10-15 kg: 10 mg SC Q2W 15-30 kg: 20 mg SC Q2W ≥30 kg: 40 mg SC Q2W Crohn disease: Children ≥6 years and Adolescents: 17-40 kg: Initial: 80 mg SC on day 1, then 40 mg SC 2 weeks later (day 15) Maintenance: 20 mg SC Q2W beginning day 29. May increase to 20 mg QW. ≥40 kg: Initial: 160 mg SC (given over 1 or 2 days), then 80 mg SC 2 weeks later (day 15) Maintenance: 40 mg SC Q2W beginning day 29. May increase to 40 mg QW. Ulcerative colitis: Children ≥5 years and Adolescents: 20-40 kg: Initial: 80 mg SC on day 1, then 40 mg SC QW for 2 doses (on day 8 and day 15) Maintenance: 40 mg SC Q2W or 20 mg SC QW beginning day 29 ≥40 kg: Initial: 160 mg SC (given over 1 or 2 days), then 80 mg SC QW for 2 doses (on day 8 and day 15) Maintenance: 80 mg SC Q2W or 40 mg SC QW beginning day 29
成人劑量	Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis: Initial: 40 mg SC Q2W, may increase to 40 mg QW or 80 mg Q2W Plaque psoriasis, Noninfectious uveitis: Initial: 80 mg SC as a single dose Maintenance: 40 mg SC Q2W beginning 1 week after initial dose. May increase to 40 mg QW Crohn disease, Ulcerative colitis: Induction: 160 mg SC (given over 1 or 2 days), then 80 mg SC 2 weeks later (day 15) Maintenance: 40 mg SC Q2W beginning day 29 Hidradenitis suppurativa: Initial: 160 mg SC (given over 1 or 2 days), then 80 mg 2 weeks later (day 15) Maintenance: 40 mg SC QW or 80 mg Q2W beginning day 29
副作用	